ArticleDermatologic therapy2022

Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness?

Gabriele Roccuzzo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.